No Data
No Data
Zacks.com Featured Highlights Include ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon
Piper Sandler Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $79
Analysts Conflicted on These Healthcare Names: Verona Pharma (VRNA), Neogen (NEOG) and ANI Pharmaceuticals (ANIP)
ANI Pharmaceuticals Is Maintained at Hold by Truist Securities
Truist Lifts Price Target on ANI Pharmaceuticals to $65 From $62, Keeps Hold Rating
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $86